{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T18:23:07Z","timestamp":1776450187017,"version":"3.51.2"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2022,6,10]],"date-time":"2022-06-10T00:00:00Z","timestamp":1654819200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,6,10]],"date-time":"2022-06-10T00:00:00Z","timestamp":1654819200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100006484","name":"Vifor Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006484","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics Open"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1007\/s41669-022-00341-7","type":"journal-article","created":{"date-parts":[[2022,6,10]],"date-time":"2022-06-10T10:03:52Z","timestamp":1654855432000},"page":"735-743","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Budget Impact of Intravenous Iron Therapy with Ferric Carboxymaltose in Patients with Chronic Heart Failure with Reduced Ejection Fraction (HFrEF) and Iron Deficiency in Switzerland"],"prefix":"10.1007","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2733-4946","authenticated-orcid":false,"given":"Elisabeth","family":"Brock","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giorgio","family":"Moschovitis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Micha T.","family":"Maeder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Otmar","family":"Pfister","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,6,10]]},"reference":[{"issue":"1","key":"341_CR1","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s12872-018-0815-3","volume":"18","author":"W Lesyuk","year":"2018","unstructured":"Lesyuk W, Kriza C, Kolominsky-Rabas P. Cost-of-illness studies in heart failure: a systematic review 2004\u20132016. BMC Cardiovasc Disord. 2018;18(1):74.","journal-title":"BMC Cardiovasc Disord"},{"key":"341_CR2","doi-asserted-by":"crossref","unstructured":"Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2016;18(8):891\u2013975.","DOI":"10.1002\/ejhf.592"},{"issue":"9","key":"341_CR3","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1038\/nrcardio.2011.77","volume":"8","author":"DJ van Veldhuisen","year":"2011","unstructured":"van Veldhuisen DJ, Anker SD, Ponikowski P, Macdougall IC. Anemia and iron deficiency in heart failure: mechanisms and therapeutic approaches. Nat Rev Cardiol. 2011;8(9):485\u201393.","journal-title":"Nat Rev Cardiol"},{"issue":"25","key":"341_CR4","doi-asserted-by":"publisher","first-page":"2436","DOI":"10.1056\/NEJMoa0908355","volume":"361","author":"SD Anker","year":"2009","unstructured":"Anker SD, Comin Colet J, Filippatos G, Willenheimer R, Dickstein K, Drexler H, et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med. 2009;361(25):2436\u201348.","journal-title":"N Engl J Med"},{"issue":"3","key":"341_CR5","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1002\/ejhf.229","volume":"17","author":"P Ponikowski","year":"2015","unstructured":"Ponikowski P, Filippatos G, Colet JC, Willenheimer R, Dickstein K, Luscher T, et al. The impact of intravenous ferric carboxymaltose on renal function: an analysis of the FAIR-HF study. Eur J Heart Fail. 2015;17(3):329\u201339.","journal-title":"Eur J Heart Fail"},{"key":"341_CR6","first-page":"ii71","volume":"8","author":"G Arutyunov","year":"2009","unstructured":"Arutyunov G. The safety of intravenous (IV) ferric carboxymaltose versus IV iron sucrose on patients with chronic heart failure (CHF) and chronic kidney disease (CKD) with iron deficiency (ID). Eur J Heart Fail. 2009;8:ii71.","journal-title":"Eur J Heart Fail."},{"key":"341_CR7","unstructured":"Clinicaltrials.gov. EFfect of ferric carboxymaltose on exercise capacity and cardiac function in patients with iron deficiency and chronic heart failure (EFFICACY-HF). 2019. https:\/\/clinicaltrials.gov\/ct2\/show\/results\/NCT00821717?term=EFFICACY-HF&rank=1."},{"issue":"3","key":"341_CR8","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1002\/ehf2.12179","volume":"4","author":"U Theidel","year":"2017","unstructured":"Theidel U, Vaatainen S, Martikainen J, Soini E, Hardt T, Doehner W. Budget impact of intravenous iron therapy with ferric carboxymaltose in patients with chronic heart failure and iron deficiency in Germany. ESC Heart Fail. 2017;4(3):274\u201381.","journal-title":"ESC Heart Fail."},{"issue":"7","key":"341_CR9","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1093\/eurjhf\/hfs083","volume":"14","author":"FS Gutzwiller","year":"2012","unstructured":"Gutzwiller FS, Schwenkglenks M, Blank PR, Braunhofer PG, Mori C, Szucs TD, et al. Health economic assessment of ferric carboxymaltose in patients with iron deficiency and chronic heart failure based on the FAIR-HF trial: an analysis for the UK. Eur J Heart Fail. 2012;14(7):782\u201390.","journal-title":"Eur J Heart Fail"},{"issue":"10","key":"341_CR10","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1016\/j.recesp.2014.10.011","volume":"68","author":"J Comin-Colet","year":"2015","unstructured":"Comin-Colet J, Rubio-Rodriguez D, Rubio-Terres C, Enjuanes-Grau C, Gutzwiller FS, Anker SD, et al. A cost-effectiveness analysis of ferric carboxymaltose in patients with iron deficiency and chronic heart failure in Spain. Rev Esp Cardiol (Engl Ed). 2015;68(10):846\u201351.","journal-title":"Rev Esp Cardiol (Engl Ed)."},{"issue":"6","key":"341_CR11","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1080\/14017431.2018.1546894","volume":"52","author":"T Hofmarcher","year":"2018","unstructured":"Hofmarcher T, Cabrales Alin D, Linde C. Cost effectiveness of implementing ESC guidelines for treatment of iron deficiency in heart failure in the Nordic countries. Scand Cardiovasc J. 2018;52(6):348\u201355.","journal-title":"Scand Cardiovasc J."},{"issue":"3","key":"341_CR12","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1002\/ehf2.12432","volume":"6","author":"S Bourguignon","year":"2019","unstructured":"Bourguignon S, Faller M, Champs FO, Moutier H, Levesque K, Caranhac G, et al. Budget impact of intravenous ferric carboxymaltose in patients with chronic heart failure and iron deficiency in France. ESC Heart Fail. 2019;6(3):559\u201369.","journal-title":"ESC Heart Fail."},{"issue":"1","key":"341_CR13","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.jval.2013.08.2291","volume":"17","author":"SD Sullivan","year":"2014","unstructured":"Sullivan SD, Mauskopf JA, Augustovski F, Jaime Caro J, Lee KM, Minchin M, et al. Budget impact analysis-principles of good practice: report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force. Value Health. 2014;17(1):5\u201314.","journal-title":"Value Health."},{"issue":"12","key":"341_CR14","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1016\/j.amjcard.2016.08.081","volume":"118","author":"H Wienbergen","year":"2016","unstructured":"Wienbergen H, Pfister O, Hochadel M, Michel S, Bruder O, Remppis BA, et al. Usefulness of iron deficiency correction in management of patients with heart failure [from the registry analysis of iron deficiency-heart failure (RAID-HF) Registry]. Am J Cardiol. 2016;118(12):1875\u201380.","journal-title":"Am J Cardiol"},{"key":"341_CR15","volume":"147","author":"C Gstrein","year":"2017","unstructured":"Gstrein C, Meyer M, Anabitarte P. Iron substitution in the treatment of chronic heart failure. Swiss Med Wkly. 2017;147: w14453.","journal-title":"Swiss Med Wkly"},{"key":"341_CR16","unstructured":"Ruschitzka F. Heart Failure Guidelines 2016. 2017. http:\/\/www.swisscardio.ch\/public\/veranstaltungskalender\/veranstaltungsarchiv\/2016\/jahrestagung16\/programm\/15.06.2016\/Ruschitzka_Frank_20160615_1545_Auditorium_B.pdf."},{"issue":"5","key":"341_CR17","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1001\/jama.2020.10262","volume":"324","author":"SP Murphy","year":"2020","unstructured":"Murphy SP, Ibrahim NE, Januzzi JL Jr. Heart failure with reduced ejection fraction: a review. JAMA. 2020;324(5):488\u2013504.","journal-title":"JAMA"},{"key":"341_CR18","unstructured":"cs healthcare consult. Specially commissioned analysis based on SwissDRG data. Data on file at Vifor Pharma Switzerland, see online appendix for further detail. 2016."},{"issue":"11","key":"341_CR19","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1093\/eurheartj\/ehu385","volume":"36","author":"P Ponikowski","year":"2015","unstructured":"Ponikowski P, van Veldhuisen DJ, Comin-Colet J, Ertl G, Komajda M, Mareev V, et al. Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiencydagger. Eur Heart J. 2015;36(11):657\u201368.","journal-title":"Eur Heart J"},{"key":"341_CR20","unstructured":"Swiss University Hospital. Specifically commissioned single-center data analysis. Data on file at Vifor Pharma Switzerland. 2016."},{"key":"341_CR21","unstructured":"Tarmed. Tarmed Online Browser\u2014Tarifversion: 1.09, g\u00fcltig ab 1.1.2018. 2022. https:\/\/www.tarmed-browser.ch\/de."},{"key":"341_CR22","unstructured":"NewIndex AG. Kantonale Taxpunktwerte 2019. 2022. https:\/\/www.newindex.ch\/wp-content\/uploads\/2019\/02\/TPW-DE-2019-2013.pdf."},{"key":"341_CR23","unstructured":"Vifor (International) Inc. Fachinformation FERINJECT Inj L\u00f6s 100 mg\/2\u00a0ml. 2022. https:\/\/compendium.ch\/product\/1080875-ferinject-inj-los-100-mg-2ml\/mpro."},{"issue":"4","key":"341_CR24","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.ahj.2013.01.017","volume":"165","author":"IT Klip","year":"2013","unstructured":"Klip IT, Comin-Colet J, Voors AA, Ponikowski P, Enjuanes C, Banasiak W, et al. Iron deficiency in chronic heart failure: an international pooled analysis. Am Heart J. 2013;165(4):575-82 e3.","journal-title":"Am Heart J"}],"container-title":["PharmacoEconomics - Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41669-022-00341-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s41669-022-00341-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41669-022-00341-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,2]],"date-time":"2022-09-02T10:35:24Z","timestamp":1662114924000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s41669-022-00341-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,10]]},"references-count":24,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["341"],"URL":"https:\/\/doi.org\/10.1007\/s41669-022-00341-7","relation":{},"ISSN":["2509-4262","2509-4254"],"issn-type":[{"value":"2509-4262","type":"print"},{"value":"2509-4254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,10]]},"assertion":[{"value":"18 May 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This work was supported by Vifor Pharma Switzerland.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"EB is an employee of HealthEcon, who was commissioned by Vifor Pharma Switzerland to conduct the analysis and prepare the first draft of this manuscript. OP reports consultant fees and or research grants from Vifor Pharma, Novartis, Pfizer, MSD, Astra Zeneca, Boehringer Ingelheim, Sanofi, and Bayer. GM reports consultant fees for taking part in advisory boards for Novartis, Bayer, Astra Zeneca, and Boehringer Ingelheim, outside of the submitted work.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The analysis described in this manuscript is based on efficacy data based on published data, publicly available resource use, cost and epidemiological data, as well as a proprietary analysis of SwissDRG data. These have been described and referenced extensively in the methods section of this manuscript. The authors would be happy to respond to further enquiries regarding the details of the analysis should these not have been answered by the information provided in the methods section. The model used in this study was provided to the journal\u2019s peer reviewers for their reference when reviewing the manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"The authors would be happy to respond to further enquiries regarding the details of the analysis should these not have been answered by the information provided in the methods section.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"All authors contributed to the conception of the work, validation of the input parameter values and drafting and revision of the manuscript.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}},{"value":"Ethics committee approval was not required for this study. In Switzerland, IRBs (i.e. cantonal\/ hospital ethics commissions) are tasked with assessing research which falls under the Humanforschungsgesetz (Human Research Act; ). KOFAM (kofam.ch) is the Federal Office of Public Health\u2019s (FOPH) portal for human research in Switzerland. KOFAM offers on its website the \u2018categorizer\u2019, a tool set up to help researchers ascertain whether their research project needs to be assessed by an ethics committee: . As the work presented here at no point in time touched on any individual or non-anonymized patient data, nor on any of the other topics covered by the Human Research Act, the Human Research Act does not apply to the work presented here, and hence ethics committee approval was not required.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The analysis presented here was not based on individual or non-anonymized patient data. The authors would like to thank patients whose aggregated, anonymized clinical trial, registry, and SwissDRG data served as the basis for deriving the parameter input values for the analysis presented here.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}